0001654954-24-012893.txt : 20241011 0001654954-24-012893.hdr.sgml : 20241011 20241011115634 ACCESSION NUMBER: 0001654954-24-012893 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241011 FILED AS OF DATE: 20241011 DATE AS OF CHANGE: 20241011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GSK plc CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15170 FILM NUMBER: 241366910 BUSINESS ADDRESS: STREET 1: 79 NEW OXFORD STREET CITY: LONDON STATE: X0 ZIP: WC1A 1DG BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 79 NEW OXFORD STREET CITY: LONDON STATE: X0 ZIP: WC1A 1DG FORMER COMPANY: FORMER CONFORMED NAME: GSK PLC DATE OF NAME CHANGE: 20220516 FORMER COMPANY: FORMER CONFORMED NAME: GLAXOSMITHKLINE PLC DATE OF NAME CHANGE: 20010105 6-K 1 a9370h.htm DIRECTOR/PDMR SHAREHOLDING a9370h
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of October 2024
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
GSK plc (the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Emma Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.2563
26
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Diana Conrad
 
b)
Position/status
Chief People Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.2563
5
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
 
2024-10-10
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
James Ford
 
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
 
Volume(s)
£15.2563
 
9
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Sally Jackson
b)
Position/status
 
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
c)
Price(s) and
 
volume(s)
Price(s)
 
Volume(s)
£15.2563
 
16
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Luke Miels
 
b)
Position/status
Chief Commercial Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
c)
Price(s) and
 
volume(s)
Price(s)
 
Volume(s)
£15.2563
 
3
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
 
2024-10-10
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
David Redfern
b)
Position/status
 
President Corporate Development
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.2563
71
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Regis Simard
 
b)
Position/status
President, Global Supply Chain
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.2563
26
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Philip Thomson
b)
Position/status
 
President, Global Affairs
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.2563
45
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Deborah Waterhouse
b)
Position/status
 
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.2563
58
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Victoria Whyte
 
b)
Position/status
Company Secretary
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024 on shares held through the Company's Share Reward Plan
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.2563
55
 
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Sally Jackson
b)
Position/status
 
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024.
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.3577
1
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dylan Jackson
 
b)
Position/status
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024.
 
c)
Price(s) and
 
volume(s)
Price(s)
Volume(s)
 
£15.3577
1
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Victoria Whyte
b)
Position/status
 
Company Secretary
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024.
 
c)
Price(s) and
 
volume(s)
Price(s)
 
Volume(s)
£15.3577
 
16
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-10-10
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Iain Whyte
b)
Position/status
 
PCA of Ms V Whyte (Company Secretary)
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 October 2024.
 
c)
Price(s) and
 
volume(s)
Price(s)
 
Volume(s)
£15.3577
 
1,105
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume
 
Price
 
 
e)
Date of the transaction
 
2024-10-10
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: October 11, 2024
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc